Evidence map›Paper›PMID 41158508›Full record

ReviewFrontiers in genetics2025

CircZFR functions in cancer from molecular networks to precision therapy.

Jinniang Nan, Min Li, Xinru Li, Yuqing Guo, Ziye Cai, Zekang Deng, Chengyi Zhan, Jiacheng Li, Shuying Liu, Ziyi Chen and 2 more

Abstract readReview
In one paragraph

Review in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jinniang Nan *School of Clinical Medicine, Nanchang Medical College, Nanchang, Jiangxi, China.
Min Li *Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Xinru Li *School of Clinical Medicine, Nanchang Medical College, Nanchang, Jiangxi, China.
Yuqing Guo *School of Clinical Medicine, Nanchang Medical College, Nanchang, Jiangxi, China.
Ziye CaiSchool of Clinical Medicine, Nanchang Medical College, Nanchang, Jiangxi, China.
Zekang DengSchool of Clinical Medicine, Nanchang Medical College, Nanchang, Jiangxi, China.
Chengyi ZhanSchool of Clinical Medicine, Nanchang Medical College, Nanchang, Jiangxi, China.
Jiacheng LiSchool of Clinical Medicine, Nanchang Medical College, Nanchang, Jiangxi, China.
Shuying LiuSchool of Clinical Medicine, Nanchang Medical College, Nanchang, Jiangxi, China.
Ziyi ChenSchool of Clinical Medicine, Nanchang Medical College, Nanchang, Jiangxi, China.
Zhenjun HuangDepartment of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Yihan YangJiangxi Provincial Key Laboratory of Respiratory Diseases, Jiangxi Institute of Respiratory Diseases, The Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CircRNAs are a class of covalently closed circular non-coding RNAs formed through back-splicing of precursor mRNAs, lacking 5' caps and 3' poly(A) tails, and are widely present in eukaryotic cells. Advances in high-throughput sequencing have revealed that circRNAs regulate gene expression and participate in disease pathogenesis, often exhibiting dual oncogenic or tumor-suppressive roles in cancer. CircZFR primarily comprises two subtypes-hsa_circ_0072088 and hsa_circ_0000345-which are derived from exons of the ZFR gene located on chromosome 5q13.3. CircZFR plays a critical regulatory role in the progression of multiple malignancies. This review systematically summarizes recent research progress on circZFR across different cancer types, elucidating its molecular mechanisms in influencing tumor proliferation, invasion, metastasis, and drug resistance through acting as a miRNA sponge, modulating signaling pathways, or directly binding to proteins. Furthermore, this review integrates the interaction networks between circZFR and key regulatory factors, unveiling its multifaceted functions in remodeling the tumor microenvironment. This review emphasizes the aberrant expression patterns of circZFR and their clinical prognostic relevance in multiple cancers, including colorectal, pancreatic, thyroid, bladder, hepatocellular, breast, lung, and cervical carcinomas, discusses its potential as a novel diagnostic biomarker or therapeutic target, and aims to provide a theoretical basis for precision cancer therapy while highlighting its translational research prospects.

Indexed as

cancercircRNAcircZFRoncogenic signalingtumor progression

Identifiers

PMID41158508
PMCPMC12558639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.